Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03540758 · ClinicalTrials.gov registry record · Phase 2
Regulation of Endogenous Glucose Production by Central KATP Channels
A Phase 2 study of Type 2 Diabetes Mellitus and Glucose Metabolism Disorders, sponsored by Meredith Hawkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03540758 is a Phase 2 study of Type 2 Diabetes Mellitus and Glucose Metabolism Disorders that is actively recruiting participants, run by Meredith Hawkins. The registered enrollment target is 100 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03540758, a Phase 2 study of Type 2 Diabetes Mellitus and Glucose Metabolism Disorders, is actively recruiting participants, sponsored by Meredith Hawkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Diazoxide
- DRUG Nicotinic acid
Study Locations (1)
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03540758
The ClinicalTrials.gov registry entry for NCT03540758 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The listed sponsor is Meredith Hawkins, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03540758 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03540758 about?
NCT03540758 is a clinical study titled "Regulation of Endogenous Glucose Production by Central KATP Channels". Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), i...
What is the current status of trial NCT03540758?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-08-01. Estimated completion is 2027-04.
What conditions does trial NCT03540758 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Glucose, High Blood.
What interventions are being tested in trial NCT03540758?
The interventions under investigation include: Placebo (DRUG), Diazoxide (DRUG), Nicotinic acid (DRUG).
Who is sponsoring clinical trial NCT03540758?
This trial is sponsored by Meredith Hawkins, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03540758 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
-
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.